This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Study to Assess Efficacy & Safety of Reparixin in ...
Clinical trial

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation (REP0211)

Read time: 1 mins
Last updated:7th Mar 2013
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ transplantion. Reparixin is the first low molecular weight blocker of CXCL8 biological activity in clinical development. Thus, the use of reparixin may emerge as a potential key component in the sequentially integrated approach to immunomodulation and control of non specific inflammatory events surrounding the early phases of pancreatic islet transplantation in type 1 diabetes (T1D) patients.
Category Value
Study start date 2013-03-07

View full details